Different molecules targeting other checkpoints such as PD-1, PD-L1 (programmed death-ligand 1) or LAG-3 (lymphocyte-activation gene 3) have rapidly been developed since, revolutionizing the treatment of a wide array of cancer types. This evidence concerns the gene LAG3 and cancer.